Edition:
United Kingdom

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

10.45USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$10.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
180,642
52-wk High
$10.59
52-wk Low
$1.46

Select another date:

Mon, Jan 8 2018

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study

* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:

BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln

* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

BRIEF-CymaBay Therapeutics granted EMA orphan drug designation for seladelpar

* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics publishes Seladelpar proof-of-concept study

* Cymabay Therapeutics announces the publication of the Seladelpar proof-of-concept study for primary biliary cholangitis in lancet gastroenterology and hepatology

BRIEF-CymaBay Therapeutics reports Q2 loss per share $0.31

* CymaBay reports second quarter 2017 financial results and provides corporate update

Select another date: